I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C.
The Liver Meeting 2016 - American Association for the Study of Liver Diseases 67th Annual Meeting 2016
Oct 20 - Late-breaking Full Abstracts Now Available
View updates: Conference Reports
Conference updates with a focus on FDA approved and experimental therapies for individuals treating hepatitis C and their families. Although conference highlights may be clinical in nature and directed at physicians, this website links to patient friendly commentary making it easier to navigate key data. Most often this noteworthy information is indexed by pharmaceutical company; depending on the conference. Begin here...
FDA Approved Viekira Pak
Dec 19, 2014 - Press Release Homepage: Hepatitis C New Drug Research and Liver Health Viekira Pak On The Blog: News and Research Viekira Pak - (ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets)
Two HCV Drugs to Be Discontinued
The Food and Drug Administration (FDA) announced that Rebetol(ribavirin; Merck) capsules and PegIntron (peginterferon alfa-2b; Merck) for Injection are being discontinued. The decision is business-related and not due to safety or efficacy issues with the drugs.
Rebetol is a nucleoside analogue indicated for chronic hepatitis C in combination with interferon alfa-2b (pegylated and nonpegylated), in patients ≥3 years of age with compensated liver disease. It is supplied as 200mg capsules in 56-, 70-, and 84-count bottles. The Rebetol discontinuation is effective February 1, 2016.
PegIntron is an antiviral indicated for treatment of chronic hepatitis C in patients with compensated liver disease. It is supplied as 50mcg/0.5mL, 80mcg/0.5mL, 120mcg/0.5mL, and 150mcg/0.5mL single-use vials and single-use pre-filled pens. No effective date is available for the PegIntron discontinuation.
June 28 2016
FDA APPROVED - EPCLUSA Gilead's Epclusa® (Sofosbuvir/Velpatasvir) to treat Genotype 1-6
Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). Gilead has set a list price of $74,760 for a 12-week course of treatment Elsewhere On The Site Prescribing Information: EPCLUSA News and Updates: EPCLUSA HCV Advocate
The "Peoples Website" also known as HCV Advocate is a great place for reviewing easy to understand conference coverage, basic information as well as updates on newly FDA approved drugs. Click here to find out what's new.
Recently HCV Advocate launched an incredible new; HCV Medications Blog with easy to find information; listed clearly by HCV genotype. Easy to navigate, easy to read.
Each month HCV Advocate puts out a newsletter with helpful articles about living with or treating the virus. An overview of approved drugs or agents still under investigation is offered as well.
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas.
It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes.
The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
Copyright 2010 Design by DynamicWP. All rights reserved.